Radiotherapy Combined With GDP (Gemcitabine, Cisplatin, Dexamethasone) Chemotherapy With or Without Chidamide in High-risk Early-stage Extranodal Nasal NK/T-cell Lymphoma
Latest Information Update: 27 Sep 2023
At a glance
- Drugs Cisplatin (Primary) ; Dexamethasone (Primary) ; Gemcitabine (Primary) ; Tucidinostat (Primary)
- Indications Extranodal NK-T-cell lymphoma
- Focus Therapeutic Use
- 15 Jul 2022 Status changed from recruiting to discontinued, according to the results published in the International Journal of Radiation Oncology, Biology, Physics.
- 15 Jul 2022 According to the results published in the International Journal of Radiation Oncology, Biology, Physics, as no trend to meet the primary endpoint of the study was observed, the enrollment was terminated early considering the possible AEs associated with chidamide administration. Follow-up time was extended until June 2021.
- 15 Jul 2022 Primary endpoint(Progression-free survival) has not been met, according to the results published in the International Journal of Radiation Oncology, Biology, Physics.